Date: 16-Aug-2019

Roches personalized cancer treatment wins FDA approval

The U.S. Food and Drug Administration approved Roche Holding AGs personalized cancer treatment, which targets tumors with specific genetic mutations, irrespective of where in the body the disease started, the agency said on Thursday. The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling. It is approved to treat certain types of solid tumors, which show rare genetic anomalies called NTRK fusions